You are here

Home » News

Press Releases from AlphaMed Press

July 13, 2021
AlphaMed Press partners with Oxford University Press to publish journals

July 6, 2021 -  Oxford University Press (OUP) and AlphaMed Press are pleased to announce that OUP will publish three AlphaMed Press journals: The Oncologist, STEM CELLS, and STEM CELLS Translational Medicine beginning January 2022.

The Oncologist is a 26-year-old monthly, peer reviewed open access publication committed to helping cancer physicians excel in the constantly changing fields of oncology and hematology through the publication of timely reviews, original studies, and commentaries. The journal aims to help oncologists understand a range of disciplines by connecting translational research and clinical practice but also looks at the socioeconomic and psychosocial factors that determine access to care and quality of life and function following cancer treatment.

June 21, 2021
COVID-19 studies are bolstered by lung cells made from induced pluripotent stem cells

Durham, NC (June 21, 2021) - A team led by researchers at Newcastle University, UK has successfully created a model of the cells found in the lungs that can be used to replicate how COVID-19 infects the airways. This information, reported today in the STEM CELLS journal, paves the way for broader studies of viral lung infections using a cost-effective system that can easily be manufactured on a large scale.

June 8, 2021
Non-altered birth cord cells boost survival of critically ill COVID-19 patients

Durham, NC ( June 8, 2021 ) - Critically ill COVID-19 patients treated with non-altered stem cells from umbilical cord connective tissue were more than twice as likely to survive as those who did not have the treatment, according to a study published today in STEM CELLS Translational Medicine.

The clinical trial, carried out at four hospitals in Jakarta, Indonesia, also showed that administering the treatment to COVID-19 patients with an added chronic health condition such as diabetes, hypertension or kidney disease increased their survival more than fourfold.

June 3, 2021
Bone marrow stem cell transplants can benefit some Type 2 diabetes patients, study shows

Durham, NC (June 3, 2021)-- Type 2 diabetes patients who are not overweight and who have had the disorder for less than a decade can benefit from stromal stem cells transplanted from their own bone marrow, according to a study published today in STEM CELLS Translational Medicine.

In a randomized clinical trial at Vinmec Research Institute of Stem Cell and Gene Technology in Hanoi, Vietnam, researchers investigated the safety and potential therapeutic value of administering bone marrow stromal stem cells to patients with Type 2 diabetes. In each case, the cells were autologous, or taken from the patients' own bodies.

A total of 30 adult patients with different body mass indexes whose Type 2 diabetes histories varied from one to 25 years were recruited for the study. Each received two infusions of the cells intravenously or by injection into an artery that supplies blood to the pancreas.

May 20, 2021
From mice to men: Study reveals potential new target for treating acute myeloid leukemia

Durham, NC (May 20, 2021) - Bone marrow failure due to acute myeloid leukemia (AML) is a significant factor behind the disease's high rate of morbidity and mortality. Previous studies in mice suggest that AML cells inhibit healthy hematopoietic (blood) stem and progenitor cells (HSPC). A study released in STEM CELLS adds to this extent of knowledge by showing how secreted cell factors, in particular a protein called transforming growth factor beta 1 (TGFβ1), leads to a breakdown in the production of healthy blood cells (a process called hematopoiesis) in humans.

The study's findings indicate that blocking TGFβ1 could improve hematopoiesis in AML patients.

May 4, 2021
Human mesenchymal stem cells show promise in treating chronic lung infections

Durham, NC (May 5, 2021) - A study released today in STEM CELLS Translational Medicine offers hope for those suffering from a chronic, difficult to treat condition called non-tuberculous mycobacteria (NTM) lung infection. The study describes how researchers at Case Western University developed a new model of NTM lung infection and then used it to show how effective human mesenchymal stem cells (hMSCs) are in treating this condition - and even which donor cells might be best for doing so.

"The potential to use human mesenchymal stem cells to treat difficult lung infections is promising," said Anthony Atala, M.D., Editor-in-Chief of STEM CELLS Translational Medicine and Director of the Wake Forest Institute for Regenerative Medicine. "This study shows the ability of using optimal donors to obtain maximum treatment success."

April 20, 2021
Clinical trial assesses stem cells’ ability to prevent major cause of preemie deaths

Durham, NC (April 20, 2021) - A phase 2 clinical trial whose results were released today in STEM CELLS Translational Medicine might point to a way to overcome bronchopulmonary dysplasia (BPD), a major cause of death in preterm infants. The study, conducted by researchers at Samsung Medical Center, Sungkyunkwan University and Asan Medical Center Children's Hospital in Seoul, evaluates the effectiveness of treating these infants by transplanting umbilical cord blood-derived mesenchymal stem cells (UCB-MSCs) directly into their tracheas.

Early results showed signs of improvement for the most immature infants included in the trial.

April 19, 2021
Fat grafts enhanced with ADSCs show promise in treating facial scleroderma

Durham, NC (April 19, 2021) - A study released today in STEM CELLS Translational Medicine suggests a new way to correct facial atrophy of localized scleroderma (LoS) in patients. It shows how applying grafts made up of the patient's own fat enhanced with adipose-derived stem cells (ADSCs) is a safe, feasible and attractive alternative to conventional fat grafting or fat grafting combined with stromal vascular fraction in treating this condition.

April 13, 2021
Aged bone marrow niche impedes function of rejuvenated hematopoietic stem cells

Durham, NC (April 13, 2021) - When leukemia strikes an older person, it is in part due to the aging of his or her hematopoietic stem cells (HSCs). These immature cells can develop into all types of blood cells, including white blood cells, red blood cells and platelets. As such, researchers have focused on rejuvenating HSCs as a way to treat leukemia.

A new study released today in STEM CELLS adds much to that level of knowledge by showing that the youthful function of rejuvenated HSCs upon transplantation depends in part on a young bone marrow "niche," which is the microenvironment surrounding stem cells that interacts with them to regulate their fate.

April 7, 2021
Stem cell therapy research could help patients with non-healing diabetic foot ulcers

Durham, NC (April 7, 2021) - According to the results of a phase 1 clinical trial just published in STEM CELLS Translational Medicine, a new stem cell therapy shows promise of making diabetes-related amputations a thing of the past. The trial involved injecting diabetes patients suffering from non-healing diabetic foot ulcers (DFU) with a cell preparation containing adult stem cells harvested from their own fat. The results showed that the treatment induced regeneration of the blood vessels surrounding the DFUs, accelerated healing - all with no serious side effects.

Pages